First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders
Funds the first human trials of a novel-mechanism psychiatric drug or a novel neuromodulatory device, with milestones gating each step.
This is the notice a psychiatric drug or device company should read first. It funds the step into people, for both modalities, under one announcement.
What qualifies is novelty of mechanism. Investigational drugs with a novel mechanism of action, or novel neuromodulatory devices, for psychiatric disorders in areas of unmet medical need. Paediatric and adult populations are both in scope, and the …
Milestone-driven early-stage clinical trials of novel mechanism of action investigational drugs and novel neuromodulatory devices for psychiatric disorders in areas of unmet medical need, in paediatric and adult populations — first-in-human and phase II drug studies assessing target engagement, pharmacological effects, safety and tolerability; proof-of-concept studies evaluating functional and clinical measures; and first-in-human and early feasibility device studies. A clinical trial is required.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up